IBDEI17K ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,21619,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,21620,0)
 ;;=205.01^^133^1317^6
 ;;^UTILITY(U,$J,358.3,21620,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21620,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,21620,1,5,0)
 ;;=5^AML, In Remission
 ;;^UTILITY(U,$J,358.3,21620,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,21621,0)
 ;;=205.10^^133^1317^49
 ;;^UTILITY(U,$J,358.3,21621,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21621,1,4,0)
 ;;=4^205.10
 ;;^UTILITY(U,$J,358.3,21621,1,5,0)
 ;;=5^CML w/o Remission
 ;;^UTILITY(U,$J,358.3,21621,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,21622,0)
 ;;=205.11^^133^1317^51
 ;;^UTILITY(U,$J,358.3,21622,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21622,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,21622,1,5,0)
 ;;=5^CML, In Remission
 ;;^UTILITY(U,$J,358.3,21622,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,21623,0)
 ;;=289.0^^133^1317^53
 ;;^UTILITY(U,$J,358.3,21623,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21623,1,4,0)
 ;;=4^289.0
 ;;^UTILITY(U,$J,358.3,21623,1,5,0)
 ;;=5^Erthryocytosis, Secondary
 ;;^UTILITY(U,$J,358.3,21623,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,21624,0)
 ;;=238.4^^133^1317^107
 ;;^UTILITY(U,$J,358.3,21624,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21624,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,21624,1,5,0)
 ;;=5^Polycytheria Rubra Vera
 ;;^UTILITY(U,$J,358.3,21624,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,21625,0)
 ;;=V58.61^^133^1317^123
 ;;^UTILITY(U,$J,358.3,21625,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21625,1,4,0)
 ;;=4^V58.61
 ;;^UTILITY(U,$J,358.3,21625,1,5,0)
 ;;=5^Warfarin/Coumadin Use
 ;;^UTILITY(U,$J,358.3,21625,2)
 ;;=Warfarin/Coumadin Use^303459
 ;;^UTILITY(U,$J,358.3,21626,0)
 ;;=282.49^^133^1317^115
 ;;^UTILITY(U,$J,358.3,21626,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21626,1,4,0)
 ;;=4^282.49
 ;;^UTILITY(U,$J,358.3,21626,1,5,0)
 ;;=5^Thalassemia NEC
 ;;^UTILITY(U,$J,358.3,21626,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,21627,0)
 ;;=289.89^^133^1317^14
 ;;^UTILITY(U,$J,358.3,21627,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21627,1,4,0)
 ;;=4^289.89
 ;;^UTILITY(U,$J,358.3,21627,1,5,0)
 ;;=5^Blood Diseases NEC
 ;;^UTILITY(U,$J,358.3,21627,2)
 ;;=^329887
 ;;^UTILITY(U,$J,358.3,21628,0)
 ;;=238.79^^133^1317^86
 ;;^UTILITY(U,$J,358.3,21628,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21628,1,4,0)
 ;;=4^238.79
 ;;^UTILITY(U,$J,358.3,21628,1,5,0)
 ;;=5^Lymph/Hematpoitc Tis NEC
 ;;^UTILITY(U,$J,358.3,21628,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,21629,0)
 ;;=287.30^^133^1317^108
 ;;^UTILITY(U,$J,358.3,21629,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21629,1,4,0)
 ;;=4^287.30
 ;;^UTILITY(U,$J,358.3,21629,1,5,0)
 ;;=5^Primary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,21629,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,21630,0)
 ;;=288.09^^133^1317^7
 ;;^UTILITY(U,$J,358.3,21630,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21630,1,4,0)
 ;;=4^288.09
 ;;^UTILITY(U,$J,358.3,21630,1,5,0)
 ;;=5^Agranulocytosis
 ;;^UTILITY(U,$J,358.3,21630,2)
 ;;=^334042
 ;;^UTILITY(U,$J,358.3,21631,0)
 ;;=284.81^^133^1317^13
 ;;^UTILITY(U,$J,358.3,21631,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21631,1,4,0)
 ;;=4^284.81
 ;;^UTILITY(U,$J,358.3,21631,1,5,0)
 ;;=5^Aplastic Anemia d/t Drugs
 ;;^UTILITY(U,$J,358.3,21631,2)
 ;;=^335245
 ;;^UTILITY(U,$J,358.3,21632,0)
 ;;=284.89^^133^1317^12
 ;;^UTILITY(U,$J,358.3,21632,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21632,1,4,0)
 ;;=4^284.89
 ;;^UTILITY(U,$J,358.3,21632,1,5,0)
 ;;=5^Aplastic Anemia d/t Chr disease
 ;;^UTILITY(U,$J,358.3,21632,2)
 ;;=^87880
 ;;^UTILITY(U,$J,358.3,21633,0)
 ;;=289.84^^133^1317^116
 ;;^UTILITY(U,$J,358.3,21633,1,0)
 ;;=^358.31IA^5^2
